Nucleosomecare Pharma LLP
About Nucleosomecare Pharma LLP
Data last updated:
Nucleosomecare Pharma LLP is a limited liability partnership (LLP) based in Faridabad, Haryana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 22 October 2020 and has been in existence for over 6 years.
The LLP is registered with the Registrar of Companies (ROC), Haryana, under LLPIN AAU-3689. The LLP has 1 GST registration on record, which is no longer active.
The LLP has a total obligation of contribution of ₹1 Lakh. It is led by designated partners Kiran Srivastava and Pooja Srivastava.
Its latest statement of accounts is for the year ended 31 March 2024. The registered office is at D 214 Second Floor Sector 81 Puri 81 High Street, Faridabad, Haryana, India – 121001.
Court records list 1 case involving the LLP, including 1 filed against it; 1 case is pending.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressD 214 Second Floor Sector 81 Puri 81 High Street, Faridabad, Haryana, India – 121001
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Nucleosomecare Pharma LLP FY 2024 filings available
Financial Statement Summary of Nucleosomecare Pharma LLP
| Statement of Account and Solvency | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|
| Income and Expenditure | ||||
| Turnover | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• |
| Total Income | •••• | •••• | •••• | •••• |
| Purchases and Direct Costs | •••• | •••• | •••• | •••• |
| Personnel Expenses | •••• | •••• | •••• | •••• |
| Administrative Expenses | •••• | •••• | •••• | •••• |
| Interest | •••• | •••• | •••• | •••• |
| Depreciation | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• |
| Tax | •••• | •••• | •••• | •••• |
| Profit After Tax | •••• | •••• | •••• | •••• |
| Profit Transferred to Partners | •••• | •••• | •••• | •••• |
| Assets and Liabilities | ||||
| Partners' Contribution | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• |
| Secured Loans | •••• | •••• | •••• | •••• |
| Unsecured Loans | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• |
| Other Liabilities and Provisions | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• |
| Loans and Advances | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• |
Financial Ratios of Nucleosomecare Pharma LLP
| Statement of Account and Solvency | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|
| Profitability | ||||
| Net Profit Margin | •••• | •••• | •••• | •••• |
| Return on Partners' Funds | •••• | •••• | •••• | •••• |
| Return on Assets | •••• | •••• | •••• | •••• |
| Liquidity and Debt | ||||
| Current Ratio | •••• | •••• | •••• | •••• |
| Debt to Partners' Funds | •••• | •••• | •••• | •••• |
| Interest Coverage | •••• | •••• | •••• | •••• |
| Efficiency and Growth | ||||
| Asset Turnover | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• |
| Turnover Growth | •••• | •••• | •••• | •••• |
| Profit Growth | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form 8. The full year-wise statements and ratios of Nucleosomecare Pharma are in the company report.
Financial statements from FY 2021
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Designated Partners of Nucleosomecare Pharma LLP
Nucleosomecare Pharma has 2 current designated partners and 1 former designated partner. Current designated partners are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kiran Srivastava Also directs: Medchar Pharma LLP | Designated Partner | 22 Oct 2020 | 5 Years 11 Months | Current |
| Pooja Srivastava | Designated Partner | 21 Mar 2023 | 3 Years 6 Months | Current |
Charges & Borrowings of Nucleosomecare Pharma LLP
Nucleosomecare Pharma LLP does not have any charges (loans) registered with the Registrar of Companies.
Legal Cases of Nucleosomecare Pharma LLP
Nucleosomecare Pharma LLP has 1 court case on record: 1 filed against it. All case is pending. Status as checked on 21 Sep 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Faridabad, Haryana | Court case (TRF) | Filed against the company by State of Haryana | Pending |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Nucleosomecare Pharma LLP
Employment history and EPFO contributions of people linked to Nucleosomecare Pharma.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Nucleosomecare Pharma LLP
Nucleosomecare Pharma LLP has 2 designated partner changes on record since 2020: 2 appointments. The latest: Pooja Srivastava was appointed as Designated Partner on 21 Mar 2023.
Credit Ratings, Litigation & Regulatory Alerts for Nucleosomecare Pharma LLP
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Nucleosomecare Pharma LLP
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Nucleosomecare Pharma LLP
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Nucleosomecare Pharma LLP
Nucleosomecare Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Nucleosomecare Pharma LLP
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nucleosomecare Pharma LLP
Nucleosomecare Pharma is an active limited liability partnership based in Faridabad, Haryana, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 22 October 2020 (6+ years old) and is registered under LLPIN AAU-3689.
Nucleosomecare Pharma has 2 current designated partners:
- Kiran Srivastava - Designated Partner
- Pooja Srivastava - Designated Partner
No. Nucleosomecare Pharma has 1 GST registration on record and it is cancelled or inactive.
The LLPIN (Limited Liability Partnership Identification Number) of Nucleosomecare Pharma is AAU-3689. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Nucleosomecare Pharma has 1 court case on record: 1 filed against it. 1 is pending.
Nucleosomecare Pharma was incorporated on 22 October 2020, making it 6+ years old. It is registered with the Registrar of Companies, Haryana.
Pooja Srivastava was appointed as Designated Partner on 21 Mar 2023. Kiran Srivastava was appointed as Designated Partner on 22 Oct 2020.
The registered office of Nucleosomecare Pharma is at D 214 Second Floor Sector 81 Puri 81 High Street, Faridabad, Haryana, India – 121001.
The total obligation of contribution is ₹1 Lakh.
Nucleosomecare Pharma operates in the pharma industry, in the drug formulation and development segment.